We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When the Trump administration rolled out its proposal to dramatically reshape drug rebates last year, the pharma industry cheered. Analysts figured the move would spread to private plans, too.